Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Johnson & Johnson : Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/12/2018 | 11:03pm CEST

By Bowdeya Tweh

Johnson & Johnson (JNJ) has accepted private-equity firm Platinum Equity's offer to buy its LifeScan business for about $2.1 billion, as the pharmaceuticals and medical-device maker moves forward with plans to streamline its business.

J&J said Tuesday that the deal for LifeScan, which makes blood-glucose monitoring equipment, is expected to close by the end of the year. More than 20 million people world-wide use LifeScan's OneTouch brand products to help them manage diabetes, J&J said.

The New Brunswick, N.J., company said it received Platinum Equity's offer in March.

Shares in J&J fell 0.4% in after-hours trading.

Write to Bowdeya Tweh at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
PLATINUM -0.52% 883.3 Delayed Quote.-4.68%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:41pJOHNSON & JOHNSON : Janssen Pharmaceutical - XARELTO Associated with Significant..
AQ
06/16JOHNSON & JOHNSON : Gift Provides Undergraduate Financial Aid and Serves Communi..
AQ
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated With Significantly Reduced ..
AQ
06/15JOHNSON & JOHNSON : XARELTO (rivaroxaban) Associated with Significantly Reduced ..
AQ
06/15KYROS LAW IS INVESTIGATING CLAIMS ON : 1,100 Invokana Lawsuits Alleging Diabetic..
PR
06/14JOHNSON & JOHNSON : Innovation Announces Five-Year Alliance with Boston Universi..
AQ
06/14JOHNSON & JOHNSON : IMBRUVICA® ibrutinib in Combination with Rituximab Showed Gr..
AQ
06/14JOHNSON & JOHNSON : New Findings in Lobectomy Described from Johnson & Johnson (..
AQ
06/14JOHNSON & JOHNSON : Data on Acetaminophen Therapy Reported by Researchers at Joh..
AQ
06/14JOHNSON & JOHNSON : Announces Binding Offer from Fortive Corporation to Acquire ..
AQ
More news
News from SeekingAlpha
05:54aPHILIP MORRIS INTERNATIONAL : Great High Dividend Income Yield Of 5.6% While Wai.. 
06/165 Safe Dividend Stocks (On Sale) For Your Retirement Portfolio 
06/16TRACKING HOW FAR THEY FELL : May Service Sector Edition 
06/153 Big Pharma Companies May Get A Big Boost From Trump 
06/15Avoiding The 'Black Hole' Of Disease Development 
Financials ($)
Sales 2018 81 525 M
EBIT 2018 24 885 M
Net income 2018 16 158 M
Debt 2018 10 673 M
Yield 2018 2,93%
P/E ratio 2018 17,76
P/E ratio 2019 16,39
EV / Sales 2018 4,16x
EV / Sales 2019 3,86x
Capitalization 329 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 144 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880
AMGEN6.39%122 422